AgingResearch.NewsJoin free

Cabozantinib

Intervention

1 paper3 findings

MeSH C558660

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Exelixis and 1 more
  • 3 of 3 findings with company ties
  • Human trial1

Outcomes

3

Objective response

upin humans1

1 study

  1. Cabozantinib increases objective response in humans (17% versus 3%; p<0.0001).

    Human trialAdvanced or metastatic clear-cell renal cell carcinoma after previous VEGFR tyrosine-kinase inhibitor treatment; compared with everolimus60 mg once a dayn = 658

    Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    The Lancet. Oncology5 Jun 2016

Progression-free survival

upin humans1HR 0.51

1 study

  1. Cabozantinib increases progression-free survival in humans (HR 0.51, 95% CI 0.41–0.62).

    Human trialAdvanced or metastatic clear-cell renal cell carcinoma after previous VEGFR tyrosine-kinase inhibitor treatment; compared with everolimus60 mg once a dayn = 658

    Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    The Lancet. Oncology5 Jun 2016

Overall survival

upin humans1HR 0.66

1 study

  1. Cabozantinib increases overall survival in humans (Median overall survival 21.4 versus 16.5 months; HR 0.66, 95% CI 0.53–0.83).

    Human trialAdvanced or metastatic clear-cell renal cell carcinoma after previous VEGFR tyrosine-kinase inhibitor treatment; compared with everolimus60 mg once a dayn = 658

    Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    The Lancet. Oncology5 Jun 2016

Latest

Related